Systemic Lupus Erythematosus Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Systemic Lupus Erythematosus Market is segmented By Treatment Type (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Antimalarials, Corticosteroids, Biologics, and Others), Route of Administration (Oral, Intravenous, and Others), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above-mentioned segments.

Market Snapshot

Systemic Lupus Erythematosus Market
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 7.1 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The systemic lupus erythematosus market is poised to grow at a CAGR of 7.1% during the forecast period.

The emergence of the COVID-19 pandemic had an adverse effect on the world economy and the healthcare system. The lockdown all over the globe has affected the supply chain of pharmaceuticals, medical devices, and biotechnological products. The severe impact of the SARS-CoV-2 virus on people with existing autoimmune diseases further increased the risk for the target population. According to the study "Impact of the COVID-19 Pandemic in Patients with Systemic Lupus Erythematosus throughout One Year" published in the Jornal of "Clinical Immunology" in October 2021, according to the findings, the impact of the COVID-19 pandemic on patients with SLE is significant and is influenced by the general population's response to the virus. In the study, older age and family contact with COVID-19 cases were key risk factors for infection, similar to the general population, however, a large number of patients did not develop COVID-19 despite having infected family members. In patients with SLE, treatment escalation, particularly with corticosteroids, is another risk linked to COVID-19.

As per the study "COVID-19 and Systemic Lupus Erythematosus: Focus on Immune Response and Therapeutics" published in October 2020, patients with autoimmune disorders, such as lupus, are prone to infections not only because of the disease's abnormal immunological responses, but also because they are frequently treated with steroids, other immune-suppressants, and immune-modulator medicines. These factors add up to a weakened immune system and an increased risk of infection. Many characteristics of lupus and COVID-19 are similar, such as patient demographics and abnormal immune responses, while others, such as gender bias, are starkly different, with lupus mostly affecting women and COVID-19 having worse outcomes in men. Lymphopenia, proinflammatory cytokines, and abnormal B and T cell responses, among other cellular, humoral, and cytokine immunological responses, may likely influence the severity and clinical consequences of COVID-19 in humans. As a result, patients with autoimmune rheumatoid arthritis have been identified as a vulnerable group at risk of severe COVID-19 infection. Hence, these factors are expected to have an impact on the target market growth in the given timeframe.

In the past decades, have observed growth in the use of corticosteroids and conventional immunosuppressive drugs, however, the unmet need for drugs with better efficacy and safety profile is still there. The major traction to this market is the continuous involvement of big biopharmaceutical companies in drugs presently in clinical trials, which boosts the growth of this market. As per the study "Updates on Clinical Trials in Systemic Lupus Erythematosus" published in 2021, Due to the complexity of systemic lupus erythematosus (SLE), researchers utilize a variety of approaches while looking for new therapeutic molecules to treat the condition. In recent clinical trials, the main focus has been on B cells and type I interferons. Small molecule inhibitors of JAK, Tyk, and Btk are presently being studied for their potential therapeutic implications in the treatment of SLE. Low-dose IL-2 and CD40 ligand blockade are used to investigate the immunoregulation of T cell activation in SLE. Bispecific antibodies having binding specificities for two different target molecules associated with T- and B-cell activation or with different elements of B-cell activation are being studied in clinical trials. A combination therapy method is also being investigated. New SLE therapy chemicals are being tested in clinical trials. Thus, the possible treatments have created lucrative opportunities for the global systemic lupus erythematosus market growth in the studied period.

However, the cost restraint and stringent regulatory guidelines for new drugs are expected to be among the primary hindrances.

Scope of the Report

Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disease that affects multiple organs with a wide variety of clinical manifestations. The Systemic Lupus Erythematosus market is segmented By Treatment Type (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Antimalarials, Corticosteroids, Biologics, and Others), Route of Administration (Oral, Intravenous, and Others), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above-mentioned segments.

By Treatment Type
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
By Route of Administration
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Biologics is Expected to Witness Better Growth Over the Forecast Period

Treatment advances in recent decades, such as the use of corticosteroids and traditional immunosuppressive drugs, have increased the life expectancy of SLE patients. Unfortunately, effective SLE management is still frequently associated with substantial drug-induced toxicity, which adds to organ function degradation and infectious complications, especially in patients with refractory disease and/or lupus nephritis. As a result, there is a gap in the market for drugs with improved efficacy and safety profiles.

A variety of biologic agents have been developed and tested in clinical trials, with a special focus on this subset of individuals whose condition is uncontrollable by current treatment regimens. Unfortunately, the majority of these studies have yielded negative results, leaving belimumab as the solely targeted therapy recognized for the treatment of SLE so far. Despite these limitations, clinical trials for various innovative biologic medicines targeting B cells, T cells, or cytokines are ongoing. When paired with established medicines, they appear to improve therapeutic efficacy. These efforts give reason to anticipate that innovative drugs for people with refractory SLE will be introduced soon. According to the study "Biologics in Systemic Lupus Erythematosus (SLE)" published in March 2022, The first biological medication approved for the treatment of SLE is belimumab (anti-BlyS). More recent research shows that adding belimumab to the standard of therapy in lupus nephritis improves the renal response rate. In randomized placebo-controlled clinical studies in SLE, other biological treatments targeting B cells (such as obinutuzumab, a newer generation anti-CD20) and the type I interferon pathway (such as anifrolumab) have also shown promise. As a result, biologics will play an increasingly important role in the treatment of SLE in the coming years.

As a result, all of the aforementioned reasons are likely to contribute to this segment's strong growth over the forecast period.

Systemic Lupus Erythematosus

North America is Expected to Hold a Significant Share in the Market

North America is expected to hold a major market share in the global systemic lupus erythematosus market owing to increased awareness about the disease in the society, better healthcare infrastructure, and a growing number of foundations and independent venture groups supporting the biopharmaceutical manufacturers. Several companies have released several general awareness programs such as the Chronic Disease Self-Management Program regarding the diagnosis, misconceptions, and treatment of the disease across the North American region. This is primarily boosted by the many non-profit organizations and funding communities supporting the cause. For instance, in December 2020, The HealthWell Foundation, an independent non-profit that provides financial assistance to Americans who are underinsured, is pleased to announce its fund for those suffering from Systemic Lupus Erythematosus has been reopened (SLE). Thus, it is expected to fuel the overall market growth during the forecast period.

In addition, the burden of growing autoimmune diseases also fuels the growth of the systemic lupus erythematosus market. As per the study "Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries" published in April 2021, An estimate of the number of systemic lupus erythematosus cases in the United States was 72.8 per 100,000 person-years. Therefore, the growing prevalence rate of systemic lupus erythematosus among people is expected to increase the demand for effective treatment, in turn, fueling the target market growth in the studies period.

Systemic Lupus Erythematosus

Competitive Landscape

With a wide range of corticosteroids and immunosuppressants already present in the market, there is a growing focus on collaborative drug development programs among the global players as well as new players in the particular geographic region. Many drugs in clinical trials, also attract several funding partners and manufacturers to head for market approval in the forecast period. Some of the major companies in this segment include GlaxoSmithKline, F. Hoffmann-La Roche AG, Pfizer Limited, Sanofi SA, Eli Lilly & Company, Viatris Inc., Novartis AG, ImmuPharma PLC, AstraZeneca, Merck & Co., Inc., and Bristl Myers Squibb Company. 

Recent Development

  • In January 2022, Eli Lilly and Company decided to discontinue the phase 3 development program for baricitinib in adults with active systemic lupus erythematosus. The decision was made based on data from 2 pivotal phase 3 trials, SLE-BRAVE-I and II, which evaluated the efficacy and safety of baricitinib in adults with active systemic lupus erythematosus.
  • In August 2021, AstraZeneca’s Saphnelo (anifrolumab-fnia) has been approved by the Food and Drug Administration (FDA) for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.

Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Systemic Lupus Erythematosus and Growing Risk Factors

      2. 4.2.2 Medical Advancements by Biopharmaceutical Companies in SLE

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Treatment

      2. 4.3.2 Several Misconceptions and Social Stigmas

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 5.1 By Treatment Type

      1. 5.1.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)

      2. 5.1.2 Antimalarials

      3. 5.1.3 Corticosteroids

      4. 5.1.4 Biologics

      5. 5.1.5 Others

    2. 5.2 By Route of Administration

      1. 5.2.1 Oral

      2. 5.2.2 Intravenous

      3. 5.2.3 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 GlaxoSmithKline

      2. 6.1.2 F. Hoffmann-La Roche AG

      3. 6.1.3 Pfizer Limited

      4. 6.1.4 Sanofi SA

      5. 6.1.5 Eli Lilly & Company

      6. 6.1.6 Viatris Inc.

      7. 6.1.7 Novartis AG

      8. 6.1.8 ImmuPharma PLC

      9. 6.1.9 Bristl Myers Squibb Company

      10. 6.1.10 AstraZeneca

      11. 6.1.11 Merck & Co., Inc.

    2. *List Not Exhaustive

Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Systemic Lupus Erythematosus Market market is studied from 2019 - 2027.

The Global Systemic Lupus Erythematosus Market is growing at a CAGR of 7.1% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Eli Lilly and Company , GlaxoSmithKline, ImmuPharma PLC , Viatris Inc. , Novartis AG are the major companies operating in Global Systemic Lupus Erythematosus Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!